Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L2-01 in Crohn's Disease
NCT07010926Phase 2Not yet recruiting
- Sponsor
- L2 Bio
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of L2-01 adipose-derived mesenchymal stem cells in Crohn's disease, sponsored by L2 Bio. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
L2-01 adipose-derived mesenchymal stem cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07010926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010926.